Hillsdale Investment Management Inc. has recently filed its 13F-HR report, revealing a total investment value of approximately $4.42 billion as of September 30, 2026. This filing is significant as it provides insight into the company's investment strategy and portfolio composition, reflecting its position in the competitive investment management industry.

Founded in Toronto, Hillsdale Investment Management Inc. is known for its strategic investment approaches. The company is categorized under the SIC description, although specific details were not provided in the filing. The firm primarily engages in investment management, focusing on various sectors and asset classes.

The latest filing, accession number 0001193125-26-457091, highlights a diverse range of investments across multiple companies. For instance, notable holdings include 10x Genomics Inc, where Hillsdale holds 116,300 shares valued at approximately $10.5 million, and Amazon.com Inc, with 96,819 shares valued at around $24.12 million. Other significant investments include AbbVie Inc and 3M Co, showcasing Hillsdale's strategy to maintain a balanced portfolio.

According to the filing, the total number of entries in the report is 666, with a total value of $4,418,713,013. This indicates a well-managed and diversified investment strategy aimed at maximizing returns while mitigating risks. The filing also lists the Chief Operating Officer and Chief Compliance Officer, Kelly Reynolds, as the signatory, emphasizing the firm's commitment to compliance and transparency.

The impact of this filing extends beyond Hillsdale itself. It may influence other investment management firms and asset managers as they assess their own portfolio strategies in light of Hillsdale's holdings. The competitive landscape in the investment management industry is continuously evolving, and firms are keen to observe how peers are allocating resources.

Looking ahead, it remains to be seen how Hillsdale will adapt its investment strategy in response to market fluctuations and economic conditions. The filing does not specify any immediate next steps, leaving stakeholders to anticipate future moves from the firm.